P0241 - Desvenlafaxine Succinate efficacy in improving functional outcomes and pain in younger, midlife, and older women and men with major depression

Abstract

Objective:

To evaluate functioning, well being, and pain outcomes with desvenlafaxine succinate (DVS) treatment in depressed men and women of different age groups.

Methods:

Data from the Sheehan Disability Scale (SDS), 5-item World Health Organization Well-Being Index (WHO-5), and Visual Analog Scale–Pain Intensity (VAS-PI) were pooled from 6 double-blind, placebo-controlled, 8-week DVS trials conducted in outpatients with major depressive disorder (MDD). Patients were divided into 3 age groups. The 18-39 and >55 years of age groups were chosen as proxies for pre- and postmenopausal status; the age group of 40-55 years, which was likely to include perimenopausal women, was also evaluated. Male patients were similarly grouped to differentiate effects of menopausal status from age on treatment response.

Results:

Patients were randomized to receive DVS 100-400mg (N=1048; 18-39 years [n=451]; 40-55 years [n=457]; >55 [n=140]) or placebo (N=718; 18-39 years [n=306]; 40-55 years [n=310]; >55 [n=102]). The final SDS, WHO-5, and VAS-PI overall pain change from baseline for the total population were significantly greater in the DVS vs the placebo group (P<0.001). Mean differences (adjusted ANCOVA) from placebo in women were: SDS: 18-39: –2.1, 40-55: –2.1, >55: –3.2; WHO-5: 18-39: +1.1, 40-55: +1.8, >55: +3.3; VAS-PI 18-39: –1.4, 40-55: –5.2, >55: –9.1. In men, results were consistent across age groups studied (SDS: 18-39: –2.9, 40-55: –3.4, >55: +2.6; WHO-5: 18-39: +1.5, 40-55: +2.4, >55: –0.3; VAS-PI 18-39: –3.0, 40-55: –7.7, >55: +2.0).

Conclusions:

DVS improves functional outcomes and pain symptoms in depressed men and women across the age groups studied.